04 Oct 2006 - PainCeptor Pharma Corp., a biopharmaceutical company focused on the development of novel therapeutics for the treatment of chronic and acute pain, announced that it has been awarded a series of milestone patents for its two lead drug development programs, NGF (nerve growth factor) and ASIC (acid sensing ion channel) antagonists.
The four patents granted PainCeptor are: 1. 'Neurotrophin Antagonists for the Treatment of Epilepsy, Alzheimer's Disease and Pain'' - patent allowed in Europe (#0930883) and Israel (#129475)
2. 'Method of Inhibiting Neurotrophin-Receptor Binding'' - patent issued in Australia (#781888)
3. "DNA Encoding a Human Proton-Gated Ion Channel and Uses Thereof'' - patent allowed in Europe (#EP-B-1025226)
4. "Method of Inhibiting Neurotrophin-Receptor Binding'' - US Divisional Patent allowed
These patents bring the total of PainCeptor's intellectual property portfolio to 39 issued patents; with an additional 45 patent applications under examination; and a further 10 provisional applications pending.
 |
www.bionity.com/news/e/58371 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/58371 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |